drugset / Trial / NCT00519324

Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer

NCT00519324 ↗

Phase 2 Completed 54 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of everolimus 10mg daily in patients with advanced gastric carcinoma (inoperable, recurrent or metastatic gastric cancer) whose cancer has progressed despite prior treatment.

Timeline

Start
2007-08
Primary completion
2009-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 10 mg Oral

Indications